SUPT7L

Across TCGA pan-cancer cohorts, SUPT7L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SUPT7L data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SUPT7L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SUPT7L expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where SUPT7L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.941	0.527	.001	16	view →
HNSC	OS	Median	All	0.347	1.000	.018	10	view →
LSCC	OS	Tertile	III,IV	0.502	0.940	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SUPT7L–LUAD (DFS)

Open the LUAD breakdown →